Spera Pharma, Inc.
Records under this name other than the patents Spera Pharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 7 of 7 · Back to Spera Pharma, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,479,798 | Method for Producing Pyrrolidine Compound Formerly held In force · High confidence | In force | High confidence | |
| US 8,981,147 | Diphosphine Ligand and Transition Metal Complex Using the Same Term ended Term ended Sep 20, 2026 · Medium confidence | Term ended | Term ended Sep 20, 2026 | Medium confidence |
| US 8,691,718 | Diphosphine Ligand and Transition Metal Complex Using the Same Lapsed on the fee record Ended Apr 8, 2026 · High confidence | Lapsed on the fee record | Ended Apr 8, 2026 | High confidence |
| US 7,208,633 | Process for Preparation of Diphosphine Compounds and Intermediates for the Process Term ended Term ended Jan 26, 2024 · High confidence | Term ended | Term ended Jan 26, 2024 | High confidence |
| US 7,135,582 | Transition Metal Complex Having Diphosphine Compound as Ligand Term ended Term ended Jan 13, 2024 · High confidence | Term ended | Term ended Jan 13, 2024 | High confidence |
| US 7,678,942 | Process for preparation of diphosphine compounds and intermediates for the process Term ended Term ended Dec 5, 2022 · From the USPTO record | Term ended | Term ended Dec 5, 2022 | From the USPTO record |
| US 8,053,604 | Process for preparation of diphosphine compounds and intermediates for the process Term ended Ended no later than Dec 5, 2022 · From the USPTO record | Term ended | Ended no later than Dec 5, 2022 | From the USPTO record |